Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity

A method of treating, ameliorating, or delaying the onset of liver fibrosis and related pathologies in a mammal in need thereof, the method comprising:

• providing a composition comprising a therapeutically effective amount of one or more Rev-erb-modulating agents (REMAs), the one or more REMAs being selected from the group consisting of 1,1-Dimethylethyl N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate;
• N-Benzyl-N-(4-chlorobenzyl)-1-(5-nitrothiophen-2-yl)methanamine;
• N-Benzyl-N-(3,4-dichlorobenzyl)-1-(5-nitrothiophen-2-yl)methanamine;
• 2-((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)-N,N-dimethylacetamide;
• SR9009;
• SR9011;
• and combinations thereof;
• and
• administering the composition to the mammal, the therapeutically effective amount comprising a quantity sufficient to modulate at least one of Rev-erbα expression, activity, and subcellular localization in at least a portion of the mammal's hepatic stellate cells (HSCs),
• wherein the one or more REMAs is contained in a vector selected from the group consisting of a plasmid, cosmid, phagemid, or virus.